Diseases of the Prostate

  • William Jackson Epperson
  • Kenneth E. Krzyzaniak


The prostate is a tubuloalveolar gland located at the base of the bladder completely surrounding the proximal male urethra. It develops embryologically as multiple endodermal outgrowths from the prostatic portion of the urethra directed by conversion of fetal testosterone to dihydrotestosterone under the influence of a 5α-reductase. At birth the gland weighs approximately 3 to 5 g. During puberty androgen-mediated maturation growth occurs, producing a gland that weighs approximately 20 g in a 20-year-old adult male.1


Prostate Cancer Benign Prostatic Hyperplasia Radical Prostatectomy Prostate Carcinoma Chronic Prostatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Isaacs JT, Steinberg GD. A guide to the physiology of the prostate. Contemp Urol 1990;5:54–68.Google Scholar
  2. 2.
    Meares EM Jr. Prostatitis syndromes: new perspectives about old woes. J Urol 1980;123:141–7.PubMedGoogle Scholar
  3. 3.
    Crawford E, Davis M. The knotty problem of prostatitis. Contemp Urol 1989;12:13–21.Google Scholar
  4. 4.
    O’Brien WM. Benign prostatic hypertrophy. Am Fam Physician 1991;44:162–71.PubMedGoogle Scholar
  5. 5.
    Boyarsky S, Jones G, Paulson DF, Prout GR Jr. A new look at bladder neck obstruction by the Food and Drug Administration regulators: guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg 1976;68:29–32.PubMedGoogle Scholar
  6. 6.
    Christensen MM, Bruskewitz RC. Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention. Urol Clin North Am 1990;17:509–16.PubMedGoogle Scholar
  7. 7.
    Loughlin KR. Medical and nonmedical therapies for benign prostatic hypertrophy. Geriatrics 1991;46:26–31.PubMedGoogle Scholar
  8. 8.
    Lepor H. Can BPH be treated with drugs? Contemp Urol 1989;7:15–23.Google Scholar
  9. 9.
    McConnell JD. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990;17: 661–70.PubMedGoogle Scholar
  10. 10.
    Lepor H. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate Suppl 1990;3:75–84.PubMedCrossRefGoogle Scholar
  11. 11.
    Carter BS, Carter B, Isaacs JT. Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate 1990;16:187–97.PubMedCrossRefGoogle Scholar
  12. 12.
    American Cancer Society. Cancer facts and figures. 1992. Atlanta, Ga. American Cancer Society; 1992.Google Scholar
  13. 13.
    Crawford ED. Benign and malignant prostatic disease. Am Fam Physician 1991;44:655–705.Google Scholar
  14. 14.
    Andriole GL, Cantalona WJ. Early diagnosis of prostate cancer. Urol Clin North Am 1987;14:657–61.PubMedGoogle Scholar
  15. 15.
    Bostwick DG. The pathology of early prostate cancer. CA Cancer J Clin 1989;39:376–91.PubMedCrossRefGoogle Scholar
  16. 16.
    Cancer of the prostate: research report. Bethesda: National Cancer Institute, 1990; NIH Publ. 91–528.Google Scholar
  17. 17.
    Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215–20.PubMedCrossRefGoogle Scholar
  18. 18.
    Crawford ED, Schutz MJ, Clejan S et al. The effect of digital rectal examination on prostate-specific antigen levels. JAMA 1992;267: 227–8.CrossRefGoogle Scholar
  19. 19.
    Crawford ED, Moon TM, Stone NM, et al. Prostate cancer awareness week: results of screening. Am J Clin Urol 1991;10:531–5.Google Scholar
  20. 20.
    Rainwater LM, Morgan WR, Knee GG, Zincke H. Prostate specific antigen testing in untreated prostatic adenocarcinoma. Mayo Clin Proc 1990;65:1118–26.PubMedCrossRefGoogle Scholar
  21. 21.
    Brawer MK, Chetner MP, Beatie JB, Buchner DM, Vesselia RL, Lange PH. Screening for prostate carcinoma with prostate specific antigen. J Urol 1992;147:841–5.PubMedGoogle Scholar
  22. 22.
    Benson NC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate-specific antigen density to enhance the predictive value of intermediate levels on prostate-specific antigen. J Urol 1992;147:817–21.PubMedGoogle Scholar
  23. 23.
    Consensus conference. The management of clinically localized prostate cancer. JAMA 1987;258:2727–30.CrossRefGoogle Scholar
  24. 24.
    Moore JJ, O’Sullivan B, Tannock IF. How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol 1988;6:1736–44.PubMedGoogle Scholar
  25. 25.
    Paulson DF. Radiotherapy versus surgery for localized prostatic cancer. Urol Clin North Am 1987;14:675–84.PubMedGoogle Scholar
  26. 26.
    Johansson JE, Adami HO, Andersson SO. High 10 year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;16:2191–6.CrossRefGoogle Scholar
  27. 27.
    Smith JA Jr. Patient selection for radical prostatectomy. Urology 1989;33 Suppl: 17–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Gross JS. Current management modalities for prostate cancer. Geriatrics 1990;45:60–68.PubMedGoogle Scholar
  29. 29.
    Zinche H. Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Urology 1989;33 Suppl 5:27–36.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • William Jackson Epperson
  • Kenneth E. Krzyzaniak

There are no affiliations available

Personalised recommendations